Treat-to-target in vasculitis: Is this a sensible approach?

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Luqmani, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ANCA; Birmingham vasculitis activity score; Cyclophosphamide; Granulomatosis with polyangiitis; Microscopic polyangiitis; Rituximab; Vasculitis; Vasculitis damage index

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; MORBIDITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; REMISSION; SERODIAGNOSIS; SYSTEMIC VASCULITIS; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; HUMANS; PATIENT CARE PLANNING; RECURRENCE; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; SYSTEMIC VASCULITIS;

EID: 84870284575     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: EUROPEAN VASCULITIS STUDY GROUP: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
2. JAYNE DR, GASKIN G, RASMUSSEN N et al.: European Vasculitis Study Group: Randomized trial of plasma exchange or highdosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
3. JONES RB, TERVAERT JW, HAUSER T et al.: EUROPEAN VASCULITIS STUDY GROUP: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
4. STONE JH, MERKEL PA, SPIERA R et al.: RAVEITN RESEARCH GROUP: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
5. EXLEY AR, BACON PA, LUQMANI RA, KITAS GD, GORDON C, SAVAGE CO, ADU D: Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80
6. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EUROPEAN VASCULITIS STUDY GROUP: EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009a; 68:318-23.
7. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994b; 87:671-8.
8. EXLEY AR, BACON PA, LUQMANI RA et al.: Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
9. DIRESKENELI H, AYDIN SZ, KERMANI TA et al.: Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011;38:1471-9.
10. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EUROPEAN VASCULITIS STUDY GROUP: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009b; 68:310-7.
11. FLOSSMANN O, BERDEN AE, DE GROOT K et al.: AND EUROPEAN VASCULITIS STUDY GROUP EUVAS: Long-term patient survival in ANCA-associated vasculitis Ann Rheum Dis 2011;70:488-94.
12. GORDON M, LUQMANI RA, ADU D et al.: Relapses in patients with a systemic vasculitis. Q J Med 1993;86:779-89.
13. SEO P, MIN YI, HOLBROOK JT et al.: Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
14. ROJO-LEYVA F, RATLIFF NB, COSGROVE DM 3RD, HOFFMAN GS: Study of 52 patients with idiopathic aortitis from a cohort of 1, 204 surgical cases. Arthritis Rheum 2000;43:901-7.
15. GARCÍA-MARTÍNEZ A, HERNÁNDEZ-RODRÍGUEZ J, ARGUIS P et al.: Development of aortic aneurysm/dilatation during the fol-Iowup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008;59:422-30.
16. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
17. DE GROOT K, HARPER L, JAYNE DR et al:, EUVAS (EUROPEAN VASCULITIS STUDY GROUP): Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
18. XIAO H, HEERINGA P, HU P et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
19. SALAMA AD, LITTLE MA: Animal models of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2012 24:1-7.
20. SALAMA AD, LITTLE MA: Animal models of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2012;24:1-7.
21. LITTLE MA, SMYTH L, SALAMA AD et al.: Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol 2009;174:1212-20.
22. XIAO H, SCHREIBER A, HEERINGA P, FALK RJ, JENNETTE JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52-64.
23. GUILLEVIN L, LHOTE F, SAUVAGET F et al.: Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994;53:334-7.
24. SAADOUN D, RESCHE-RIGON M, THIBAULT V, PIETTE JC, CACOUB P: Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54:3696-706.
25. DE VITA S, QUARTUCCIO L, ISOLA M et al.: A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-53.
26. TOMASSON G, GRAYSON PC, MAHR AD, LAVALLEY M, MERKEL PA: Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology (Oxford) 2012;51:100-9.
27. SLOT MC, TERVAERT JW, BOOMSMA MM, STEGEMAN CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004;51:269-73.
28. BOOMSMA MM, STEGEMAN CA, VAN DER LEU MJ et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-33.
29. TERVAERT JW, HUITEMA MG, HENE RJ et al.: Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11.
30. FINKIELMAN JD, MERKEL PA, SCHROEDER D et al:, WGET Research Group: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611-9.
31. MURPHY JM, BALAN KK, TOMS A, GOMEZ-ANSON B, LOCKWOOD M: Radiolabeled leucocyte imaging in diffuse granulomatous involvement of the meninges in Wegener's granulomatosis: scintigraphic findings and their role in monitoring treatment response to specific immunotherapy (humanized monoclonal antilymphocyte antibodies). AJNR Am J Neuroradiol 2000;21:1460-5.
32. ALLEN SD, HARVEY a: Imaging of Wegener's granulomatosis. Br J Radiol 2007;80:757-65
33. WALTER MA, MELZER RA, SCHINDLER C, MULLER-BRAND J, TYNDALL A, NITZSCHE EU: The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005;32:674-81.
34. TREGLIA G, MATTOLI MV, LECCISOTTI L, FERRACCIOLI G, GIORDANO A: Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol 2011;30:1265-75.
35. FUCHS M, BRIEL M, DAIKELER T et al.: The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012;39:344-53.
36. ARIDA A, KYPRIANOU M, KANAKIS M, SFIKAKIS PP: The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord 2010;11:44.
37. HABIB HM, ESSA AA, HASSAN AA: Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis. Clin Rheumatol 2012;31:231-7.
38. LUQMANI R, SUPPIAH R, EDWARDS CJ et al.: Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology (Oxford) 2011;50:697-702.
39. PHILLIP R, LUQMANI R: Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008;26(Suppl. 51):S94-104.
40. WALSH M, MUKHTYAR C, MAHR A et al.: Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 2011;63:1055-61.
41. MERKEL PA, AYDIN SZ, BOERS M et al.: The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 2011;38:1480-6.
42. LAPRAIK C, WATTS R, BACON P et al:, BSR AND BHPR STANDARDS, GUIDELINES AND AUDIT WORKING GROUP: BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007;46:1615-6.
43. HELLMICH B, FLOSSMANN O, GROSS WL et al.: EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
44. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
45. JONES RB et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
46. FLOSSMANN O, BASLUND B, BRUCHFELD A et al.: Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009;68:1125-30.
47. EXLEY AR, BACON PA, LUQMANI RA, KITAS GD, CARRUTHERS DM, MOOTS R: Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998;37:57-63.
48. TALAR-WILLIAMS C, HIJAZI YM, WALTHER MM et al.: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
49. SUPPIAH R, JUDGE A, BATRA R et al.: A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011;63:588-96.
50. LITTLE MA, NIGHTINGALE P, VERBURGH CA et al.: EUROPEAN VASCULITIS STUDY (EUVAS) GROUP: Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
51. MCKINNEY EF, LYONS PA, CARR EJ et al.: A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010;16:586-91.